Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alphavirus Infections | 2 | 2023 | 4 | 1.120 |
Why?
|
| HIV Infections | 19 | 2018 | 2303 | 1.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 12 | 2015 | 215 | 1.050 |
Why?
|
| Risk-Taking | 7 | 2015 | 451 | 0.990 |
Why?
|
| Alphavirus | 2 | 2023 | 7 | 0.960 |
Why?
|
| Aedes | 1 | 2023 | 34 | 0.880 |
Why?
|
| Cardiovascular Diseases | 5 | 2021 | 664 | 0.840 |
Why?
|
| Adolescent Behavior | 4 | 2015 | 253 | 0.830 |
Why?
|
| Risk Reduction Behavior | 3 | 2019 | 127 | 0.760 |
Why?
|
| Bunyaviridae | 1 | 2020 | 4 | 0.740 |
Why?
|
| Puerto Rico | 24 | 2017 | 1378 | 0.660 |
Why?
|
| School Health Services | 1 | 2015 | 81 | 0.500 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2013 | 121 | 0.450 |
Why?
|
| Adolescent Development | 1 | 2010 | 31 | 0.360 |
Why?
|
| Male | 32 | 2021 | 20025 | 0.360 |
Why?
|
| Female | 32 | 2021 | 20969 | 0.350 |
Why?
|
| Social Behavior | 1 | 2010 | 131 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 864 | 0.330 |
Why?
|
| Prospective Studies | 7 | 2021 | 1378 | 0.330 |
Why?
|
| Humans | 36 | 2023 | 37093 | 0.330 |
Why?
|
| Adolescent | 13 | 2021 | 5363 | 0.320 |
Why?
|
| Primary Health Care | 3 | 2021 | 294 | 0.320 |
Why?
|
| Hepatitis C | 4 | 2013 | 125 | 0.320 |
Why?
|
| Cross-Sectional Studies | 9 | 2021 | 2721 | 0.290 |
Why?
|
| Middle Aged | 19 | 2021 | 10129 | 0.270 |
Why?
|
| Chikungunya virus | 2 | 2022 | 16 | 0.270 |
Why?
|
| Spain | 3 | 2021 | 36 | 0.270 |
Why?
|
| Pilot Projects | 3 | 2015 | 661 | 0.250 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 155 | 0.250 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 730 | 0.230 |
Why?
|
| Aged | 12 | 2021 | 6741 | 0.230 |
Why?
|
| Adult | 23 | 2021 | 11712 | 0.220 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 262 | 0.220 |
Why?
|
| Arboviruses | 1 | 2022 | 5 | 0.220 |
Why?
|
| Social Class | 1 | 2005 | 247 | 0.220 |
Why?
|
| Multimedia | 3 | 2013 | 17 | 0.220 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2015 | 189 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 109 | 0.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 221 | 0.190 |
Why?
|
| Risk Assessment | 3 | 2018 | 753 | 0.190 |
Why?
|
| Culicidae | 1 | 2020 | 24 | 0.180 |
Why?
|
| Cohort Studies | 8 | 2015 | 1492 | 0.180 |
Why?
|
| Slovenia | 1 | 2019 | 1 | 0.180 |
Why?
|
| Croatia | 1 | 2019 | 4 | 0.180 |
Why?
|
| Portugal | 1 | 2019 | 9 | 0.180 |
Why?
|
| France | 1 | 2019 | 17 | 0.180 |
Why?
|
| Turkey | 1 | 2019 | 22 | 0.180 |
Why?
|
| Genome, Viral | 1 | 2020 | 109 | 0.170 |
Why?
|
| Mexico | 1 | 2020 | 240 | 0.170 |
Why?
|
| Sex Factors | 5 | 2018 | 898 | 0.160 |
Why?
|
| Viral Load | 3 | 2015 | 312 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2018 | 59 | 0.160 |
Why?
|
| Prevalence | 7 | 2021 | 1455 | 0.150 |
Why?
|
| Forecasting | 1 | 2018 | 128 | 0.150 |
Why?
|
| Phylogeny | 1 | 2020 | 644 | 0.140 |
Why?
|
| Pancytopenia | 1 | 2015 | 3 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2016 | 75 | 0.140 |
Why?
|
| Risk Factors | 8 | 2021 | 3562 | 0.130 |
Why?
|
| Animals | 2 | 2023 | 15081 | 0.130 |
Why?
|
| Anemia | 1 | 2014 | 45 | 0.120 |
Why?
|
| Exercise | 1 | 2019 | 613 | 0.120 |
Why?
|
| Survival Rate | 3 | 2018 | 311 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2019 | 517 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 1067 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2011 | 41 | 0.110 |
Why?
|
| Quality of Life | 1 | 2017 | 481 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2014 | 854 | 0.110 |
Why?
|
| Malaria, Vivax | 1 | 2012 | 4 | 0.100 |
Why?
|
| Young Adult | 6 | 2021 | 4268 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 974 | 0.100 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 68 | 0.100 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 9 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 389 | 0.100 |
Why?
|
| Child | 3 | 2021 | 3131 | 0.090 |
Why?
|
| Health Education | 1 | 2013 | 338 | 0.090 |
Why?
|
| Logistic Models | 3 | 2021 | 923 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 583 | 0.090 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 458 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2379 | 0.090 |
Why?
|
| Colombia | 2 | 2022 | 20 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2018 | 2026 | 0.080 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 25 | 0.080 |
Why?
|
| Age Factors | 3 | 2016 | 1033 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 385 | 0.070 |
Why?
|
| Health Care Reform | 1 | 2005 | 32 | 0.060 |
Why?
|
| Anti-HIV Agents | 2 | 2015 | 420 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 1046 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2008 | 225 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 1418 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 57 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 441 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1369 | 0.050 |
Why?
|
| Immune Sera | 1 | 2021 | 59 | 0.050 |
Why?
|
| Peru | 1 | 2021 | 30 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 62 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 83 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 885 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2013 | 339 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 922 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2001 | 230 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 610 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 91 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 623 | 0.040 |
Why?
|
| North America | 1 | 2018 | 67 | 0.040 |
Why?
|
| Psychophysiologic Disorders | 1 | 1997 | 5 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2021 | 646 | 0.040 |
Why?
|
| Prognosis | 1 | 2018 | 739 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 77 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 28 | 0.030 |
Why?
|
| Unemployment | 1 | 2014 | 23 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 77 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 441 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 1997 | 583 | 0.020 |
Why?
|
| Depression | 1 | 1997 | 712 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 225 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 348 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 175 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 212 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 388 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 65 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 275 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 208 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 325 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2006 | 62 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1742 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 537 | 0.020 |
Why?
|
| HIV | 1 | 2006 | 98 | 0.020 |
Why?
|
| Wasting Syndrome | 1 | 2004 | 5 | 0.020 |
Why?
|
| Needle Sharing | 1 | 2004 | 8 | 0.020 |
Why?
|
| Heroin Dependence | 1 | 2004 | 23 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 22 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 85 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 313 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2000 | 4 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2000 | 18 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 36 | 0.010 |
Why?
|
| Heterosexuality | 1 | 2000 | 88 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1997 | 215 | 0.010 |
Why?
|
| Registries | 1 | 1997 | 335 | 0.010 |
Why?
|